Insmed
INSM | NASDAQ
$122.88
+$1.72 (+1.42%)
At close: Nov 16, 2026, 4:00 PM ET
$122.06
-$0.82 (-0.67%)
After-hours:
Nov 16, 2026, 7:44 PM ET
Insmed Company Profile
Company profile explainedCompany Profile
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Key Executives
| Name | Position |
|---|---|
| William H. Lewis | President, Chief Executive Officer & Chairman |
| Michael Alexander Smith | Chief Legal Officer & Corporate Secretary |
| Roger Adsett | Chief Operating Officer |
| Sara Bonstein | Chief Financial Officer |
| Brian K. Kaspar | Chief Scientific Officer |
| Bryan Dunn | Vice President of Investor Relations |
| Christie Camelio | Chief Compliance Officer |
| Claire Mulhearn | Vice President of Corporate Communications |
| Eugene J. Sullivan FCCP | Chief Product Strategy Officer |
| Martina Flammer | Chief Medical Officer |
| S. Nicole Schaeffer | Chief People Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Oct 29, 2026 | 10-Q | Quarterly Report |
| Oct 20, 2026 | 4 | Filing |
| Oct 20, 2026 | 4 | Filing |
| Oct 20, 2026 | 3 | Filing |
| Oct 20, 2026 | 3 | Filing |
| Oct 20, 2026 | 8-K | Current Report |
| Oct 05, 2026 | 8-K | Current Report |
| Sep 11, 2026 | 4 | Filing |
| Aug 19, 2026 | 4 | Filing |
Insmed
| Country | United States |
| IPO Date | Jun 1, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,664 |
| CEO | William H. Lewis |
Contact Details
700 US Highway 202/206 Bridgewater,
New Jersey 08807 United States
Stock Details
| Ticker Symbol | INSM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001104506 |
| CUSIP Number | 457669307 |
| ISIN Number | US4576693075 |
| SIC Code | 2834 |
Recent News
- 14 hours ago / seekingalpha.comInsmed Incorporated (INSM) Presents at Jefferies Global Healthcare Conference 2026 Transcript
- 10 days ago / seekingalpha.comInsmed: A Blockbuster Launch, Priced Ahead Of Its Own Guidance
- 13 days ago / prnewswire.comInsmed to Present at November and December 2026 Investor Conferences
- 17 days ago / seekingalpha.comInsmed Incorporated (INSM) Q3 2026 Earnings Call Transcript
- 18 days ago / zacks.comINSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance
- 19 days ago / marketbeat.comWhat Insmed (INSM) Said on Its Q3 Earnings Call
- 19 days ago / zacks.comInsmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
- 19 days ago / zacks.comInsmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
- 19 days ago / prnewswire.comInsmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
- 26 days ago / zacks.comInsmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Add to Watchlist
Select watchlists to add or remove INSM